- Research Grants
Daniel Moreira Silva is graduated in Biomedicine with a degree in Pharmacology and a Master in Applied Cellular and Structural Biology from the Federal University of Uberlândia (UFU) and a PhD from the Postgraduate Program in Neuroscience and Cognition. Develops research focusing on the interaction between the cognitive, pharmacological and metabolic aspects of neurodegenerative diseases and the endocannabinoid system. He is currently Substitute Professor of Pharmacology and Biophysics at the Federal University of Uberlândia. (Source: Lattes Curriculum)
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by cognitive impairment, increase of fear- and anxiety-related behaviors and reaction time in attention tasks and importantly, a marked deficit of spatial and operational memory. AD is also known by neurofibrilar tangles, generated by hyperphosphorylated tau protein accumulation. Studies showed that cannabinoid drugs...
Alzheimer's disease (AD) is characterized by the gradual and continuous increase of multiple cognitive deficits. Cognitive alterations are correlated with reduction of volume and/or synaptic plasticity in regions such as hippocampus and neocortex. Recent studies indicate a great influence of the endocannabinoid system on AD progress, regulating mechanisms of neuroplasticity and cognitiv...
(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)
|Data from Web of Science|